Saturday 17 October 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
31.96
1.84
−5.44%
Follow CSTL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 3 |
| (2.69%) | (5.21%) | (2.85%) | (4.20%) | ||
| (2.27%) | (4.35%) | (2.45%) | (3.51%) | ||
ROIC |
(11.50%) | (14.72%) | (9.90%) | (9.40%) | |
Return on Tangible Assets |
(3.16%) | (6.20%) | (3.37%) | (4.99%) | |
Average Days of Receivables |
52.57 | 46.00 | 45.38 | 49.39 | |
Free Cash Flow per Share |
0.87 | 0.98 | 0.15 | (0.01) | |
Free Cash Flow |
25.42 | 28.37 | 4.56 | (0.45) | |
Capital Expenditures |
(36.36) | (35.98) | (43.69) | (43.09) | |
| Other line items | |||||
Cash ROIC |
3.32% | 3.63% | 0.62% | (0.06%) | |
Accounts Receivable Turnover |
6.89 | 7.28 | 6.89 | 7.10 | |
Accounts Payable Turnover |
7.24 | 5.55 | 6.39 | 7.11 | |
Inventory Turnover |
9.05 | 7.73 | 8.69 | 8.58 | |
Average Days of Payables |
64.69 | 96.15 | 73.01 | 43.43 | |
Days of Inventory on Hand |
45.83 | 52.69 | 50.79 | 47.53 | |
Tax Rate |
(0.35) | (0.18) | (0.27) | 0.01 | |
Research and Development Expense of Revenue |
14.59% | 15.06% | 15.79% | 15.52% | |
Selling, General and Administrative Expense of Revenue |
64.79% | 66.62% | 69.31% | 68.20% | |
Share Based Compensation of Revenue |
13.37% | 13.33% | 13.09% | 12.56% | |
Interest Coverage |
(226.84) | (497.79) | (163.99) | (85.62) | |
Operating CF/Net income |
(5.05) | (2.66) | (3.76) | (2.20) | |
Depreciation/Fixed assets |
0.44 | 0.38 | 0.12 | 0.13 | |
Capex/Depreciation |
(0.97) | (0.98) | (3.74) | (3.28) | |
Revenue per Share |
11.82 | 11.88 | 11.37 | 11.75 | |
Operating CF per Share |
2.13 | 2.22 | 1.61 | 1.40 | |
Capex per Share |
(1.25) | (1.24) | (1.46) | (1.42) | |
Capex to Sales |
0.11 | 0.10 | 0.13 | 0.12 |
Columns are period end dates